Info
AE_PAZOPANIB
AEs such as hypertension (50%) within 1st 18 weeks, diarrhea, n/v, abdominal pain, lipase elevated (30%), risk of GI situlas and/or perforations, fatigue, depigmentation, bleeding complications with hematuria, epistaxis, and hemoptysis, increased risk of arterial thrombolic envents (MI, angina, TIA and stroke), proteinuria (8%), and etc
Siblings
- AE_ABVD
- AE_ACT
- AE_ALECTINIB
- AE_ALIMTA
- AE_ALPELISIB
- AE_BENDAMUSTINE
- AE_CCRT
- AE_CDK46
- AE_CRIZOINIB
- AE_DABRAFENIB
- AE_ENHERTU
- AE_ERIBULIN
- AE_FOLFOX
- AE_GLIVEC
- AE_HERCEPTIN
- AE_LANREOTIDE
- AE_LAPATINIB
- AE_LAR
- AE_LETROZOLE
- AE_OLAPARIB
- AE_OSIMERTINIB
- AE_PAZOPANIB
- AE_PEMIGATINIB
- AE_PERTUZUMAB
- AE_RAMUCIRUMAB
- AE_RECTAL
- AE_REGORAFENIB
- AE_SORAFENIB
- AE_SUNITINIB
- AE_TAS102
- AE_TAXOTERECDDP
- AE_TOPOTECAN
- AE_UFT
- AE_VEMURAFENIB
- AE_VINORELBINE
- AE_XELOX